about
SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancerMechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemiaMicroRNA fingerprints during human megakaryocytopoiesisEpithelial-mesenchymal transition-derived cells exhibit multilineage differentiation potential similar to mesenchymal stem cellsMicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemiaOrigins of the tumor microenvironment: quantitative assessment of adipose-derived and bone marrow-derived stromaOxygen sensing mesenchymal progenitors promote neo-vasculogenesis in a humanized mouse model in vivoMutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemiaMitochondrial Profiling of Acute Myeloid Leukemia in the Assessment of Response to Apoptosis Modulating DrugsPronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104Human extramedullary bone marrow in mice: a novel in vivo model of genetically controlled hematopoietic microenvironmentSelection of chronic lymphocytic leukemia binding peptides.An in vivo propagated human acute myeloid leukemia expressing ABCA3.Studying the right cell in acute myelogenous leukemia: dynamic changes of apoptosis and signal transduction pathway protein expression in chemotherapy resistant ex-vivo selected "survivor cells".Triterpenoids display single agent anti-tumor activity in a transgenic mouse model of chronic lymphocytic leukemia and small B cell lymphoma.Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia.Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders.A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia.2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome.CXC chemokine receptor 4 expression, CXC chemokine receptor 4 activation, and wild-type nucleophosmin are independently associated with unfavorable prognosis in patients with acute myeloid leukemiaPhase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia.Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progressionPharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis inductionSimultaneous activation of p53 and inhibition of XIAP enhance the activation of apoptosis signaling pathways in AML.Platelet-derived growth factor BB mediates the tropism of human mesenchymal stem cells for malignant gliomas.Mesenchymal stem cells promote mammosphere formation and decrease E-cadherin in normal and malignant breast cells.Blockade of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase and murine double minute synergistically induces Apoptosis in acute myeloid leukemia via BH3-only proteins Puma and Bim.Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenibTargeting mantle cell lymphoma metabolism and survival through simultaneous blockade of mTOR and nuclear transporter exportin-1Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITDCeramide promotes apoptosis in chronic myelogenous leukemia-derived K562 cells by a mechanism involving caspase-8 and JNK1,25-dihydroxyvitamin D3 enhances the apoptotic activity of MDM2 antagonist nutlin-3a in acute myeloid leukemia cells expressing wild-type p53.Evaluation of apoptosis induction by concomitant inhibition of MEK, mTOR, and Bcl-2 in human acute myelogenous leukemia cells.AML-induced osteogenic differentiation in mesenchymal stromal cells supports leukemia growth.Preclinical antileukemic activity, toxicology, toxicokinetics and formulation development of triptolide derivative MRx102.IKK inhibition by BMS-345541 suppresses breast tumorigenesis and metastases by targeting GD2+ cancer stem cells.Case series of patients with acute myeloid leukemia receiving hypomethylation therapy and retrospectively found to have IDH1 or IDH2 mutationsInduction of p53-mediated transcription and apoptosis by exportin-1 (XPO1) inhibition in mantle cell lymphoma.Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia
P50
Q24295146-DE6CDB44-CF2A-4C22-A5F5-32640A34AC36Q24313505-BB1E389D-2201-4CBC-A891-85C031A7B1D8Q24546361-DA9ACC7F-1A85-4262-9477-D432F8F342C1Q24599620-A40B2E67-2FDB-43ED-8FAB-44BFF63779ABQ24655915-A5185B2F-BF67-4AD4-A619-A9ACBDF66A64Q27309626-D86E7D19-51DB-42B3-994B-379A6FE383F0Q27320392-63E03D14-B77D-407A-9BCF-8A620C94FE15Q27851423-1C0C0FF0-03F9-4D74-B03C-4108FB8E1D48Q28189439-2F9A10CE-D464-4726-91B0-4A1A814C7B3DQ28548058-8D4A5C5F-469D-45AE-B5AE-82273137396AQ28741513-3E460133-F3D8-4CF4-B1E9-59F69C74980EQ30514797-32C838AA-E342-4CC4-9944-B88C4D615360Q33193068-DB25A760-FA08-4DD9-B660-B845A0C5D850Q33196143-FF0A7BF1-2D6F-4ACA-94EF-2E06493B34FFQ33266765-DC231E4C-9051-4334-95FC-02D3D2A49AFBQ33288957-BF2CD510-7668-4727-AB0F-0C9B5DD0BBC3Q33343191-A1DB257C-FF60-4D24-BD8E-F18299D469C9Q33343495-9E92B7C0-8B7D-4043-BFB6-C93B332BF19EQ33360707-7A479849-476D-4DF8-AF41-0A2787CC624CQ33366921-1CB089D7-BCC7-4146-8E29-4F798B8B0CADQ33410331-79469AE6-FABF-450D-8B08-5B85F942066EQ33420436-E58F9DA1-500B-4DB2-A572-5734E854A730Q33427809-E1250D6B-B53F-4931-A103-3FFEE19B16FBQ33561797-EC111139-4BB1-42FF-856D-D5D9123028FDQ33597514-53243A75-28BC-451A-9BA3-C3C7B52F2F52Q33609232-BF6A78A3-26EB-46BF-9527-C7739E482DA3Q33680909-D619E7F3-001C-4822-B2B1-F3B60ACF48D6Q33732534-275BB0DE-F5A4-4497-B406-755F4873E3D5Q33772438-EE73EDFB-FC57-4D60-98C0-D586D986DA46Q33798463-5887AA0E-F256-4DD0-9280-81569FA24CC5Q33798909-1FED8108-5DDC-4832-B22E-E23480D57BFDQ33810952-292CDA2F-A288-4D05-9F11-87D1225F11BEQ33843653-D44F347B-992C-47FD-A572-47229711022BQ33875609-FB1D9CEE-4240-484B-A7A3-FE0A5ABF8E98Q33877778-787158AB-B448-40AA-837E-FD1CAB1F65B5Q33880729-2081D522-6678-48B4-857E-782546E44E3FQ33913799-62F730B2-CDFC-4786-87BE-FFE247B46392Q33929924-004F0B75-A2E2-459B-AC43-A0C4D8E2E9A7Q33934010-CC904465-DA80-4028-9EB8-C7D0353910E4Q33943277-382B56DC-9AC6-4A92-993B-8C20ECF91C70
P50
name
Michael Andreeff
@ast
Michael Andreeff
@en
Michael Andreeff
@es
Michael Andreeff
@nl
type
label
Michael Andreeff
@ast
Michael Andreeff
@en
Michael Andreeff
@es
Michael Andreeff
@nl
prefLabel
Michael Andreeff
@ast
Michael Andreeff
@en
Michael Andreeff
@es
Michael Andreeff
@nl